Shockwave Medical is a medical devices business based in the US. Shockwave Medical shares (SWAV) are listed on the NASDAQ and all prices are listed in US Dollars. Shockwave Medical employs 1,468 staff and has a trailing 12-month revenue of around $788 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $165.93 - $334.90 |
|---|---|
| 50-day moving average | $326.86 |
| 200-day moving average | $241.38 |
| Wall St. target price | $324.27 |
| PE ratio | 78.7647 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $4.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Shockwave Medical stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Shockwave Medical's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Shockwave Medical's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 79x. In other words, Shockwave Medical shares trade at around 79x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Shockwave Medical's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $180.3 million.
The EBITDA is a measure of a Shockwave Medical's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $788 million |
|---|---|
| Operating margin TTM | 19.38% |
| Gross profit TTM | $424.7 million |
| Return on assets TTM | 8.68% |
| Return on equity TTM | 24.73% |
| Profit margin | 20.75% |
| Book value | $20.04 |
| Market Capitalization | $12.6 billion |
TTM: trailing 12 months
We're not expecting Shockwave Medical to pay a dividend over the next 12 months.
Over the last 12 months, Shockwave Medical's shares have ranged in value from as little as $165.93 up to $334.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Shockwave Medical's is 0.879. This would suggest that Shockwave Medical's shares are less volatile than average (for this exchange).
Shockwave Medical, Inc. , a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.